Potent inhibition of tumoral hypoxia-inducible factor 1α by albendazole

[1]  N. Ferrara,et al.  Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. , 2009, Trends in pharmacological sciences.

[2]  V. Heinemann,et al.  Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. , 2009, European journal of cancer.

[3]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[4]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[5]  R. Kerbel,et al.  Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy. , 2009, Cancer cell.

[6]  M. Links,et al.  Inhibition of Cell Proliferation, Vascular Endothelial Growth Factor and Tumor Growth by Albendazole , 2009, Cancer investigation.

[7]  L. Ellis,et al.  Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy , 2008, Clinical Cancer Research.

[8]  G. Semenza.  Hypoxia‐inducible factor 1 and cancer pathogenesis , 2008, IUBMB life.

[9]  Giovanni Mazzoni,et al.  Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice , 2008, Cancer Chemotherapy and Pharmacology.

[10]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[11]  G. Semenza.  Evaluation of HIF-1 inhibitors as anticancer agents. , 2007, Drug discovery today.

[12]  D. Chung,et al.  Hypoxia Inducible Factor-1–Independent Pathways in Tumor Angiogenesis , 2007, Clinical Cancer Research.

[13]  D. Morris,et al.  Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. , 2007, Biochemical pharmacology.

[14]  R. Johnson,et al.  Hypoxia: A key regulator of angiogenesis in cancer , 2007, Cancer and Metastasis Reviews.

[15]  G. Melillo,et al.  Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy , 2006, Molecular Cancer Research.

[16]  Lisa I. Wang,et al.  Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice , 2006, Clinical Cancer Research.

[17]  Napoleone Ferrara,et al.  VEGF as a Therapeutic Target in Cancer , 2005, Oncology.

[18]  Peter Carmeliet,et al.  VEGF as a Key Mediator of Angiogenesis in Cancer , 2005, Oncology.

[19]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[20]  K. Kivirikko,et al.  Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  B. Brüne,et al.  Nitric oxide reverses desferrioxamine- and hypoxia-evoked HIF-1alpha accumulation--implications for prolyl hydroxylase activity and iron. , 2005, Experimental cell research.

[22]  Lisa I. Wang,et al.  Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis , 2005, Cancer Chemotherapy and Pharmacology.

[23]  Richard P. Hill,et al.  Acute Hypoxia Enhances Spontaneous Lymph Node Metastasis in an Orthotopic Murine Model of Human Cervical Carcinoma , 2004, Cancer Research.

[24]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[25]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[26]  J. Horton.  Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations , 2002, Current opinion in infectious diseases.

[27]  Jack A Roth,et al.  The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. , 2002, Molecular cancer therapeutics.

[28]  Jack A Roth,et al.  Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  D. Morris,et al.  Pilot Study of Albendazole in Patients with Advanced Malignancy , 2001, Oncology.

[30]  D. Morris,et al.  In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. , 2001, Cancer letters.

[31]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[32]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[33]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[34]  E. Lacey.  The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. , 1988, International journal for parasitology.

[35]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[36]  N. Ferrara,et al.  VEGF inhibition: insights from preclinical and clinical studies , 2008, Cell and Tissue Research.

[37]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[38]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[39]  G. Semenza,et al.  HIF-1: Using Two Hands to Flip the Angiogenic Switch , 2004, Cancer and Metastasis Reviews.

[40]  R. L. Brady,et al.  Comparison of inhibition of polymerisation of mammalian tubulin and helminth ovicidal activity by benzimidazole carbamates. , 1987, Veterinary parasitology.